Voyager Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.85
Dividend & YieldN/A$ (N/A)
Beta 0.89
Market capitalization 213.88M
Operating cash flow 10.93M
ESG Scores unknown

Company description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 61.1M 83.43M -154.11M -1.78M
Total Cashflows From Investing Activities 26.47M -90.48M 113M 65.91M
Net Borrowings
Total Cash From Financing Activities 4.75M 80.99M 3.16M 612k
Change To Operating Activities -5.4M 13.51M -909k -2.21M
Issuance Of Stock 4.75M 80.99M 3.16M 612k
Net Income -88.29M -43.6M 36.74M -71.2M
Change In Cash 15.33M 39.18M 19.44M 12.99M
Effect Of Exchange Rate
Total Cash From Operating Activities -15.89M 48.67M -96.72M -53.52M
Depreciation 2.12M 2.77M 3.82M 5.17M
Change To Account Receivables -18.5M -18.5M 10.48M 7.28M
Other Cashflows From Financing Activities
Change To Netincome 14.58M 11.06M 7.26M 9.21M
Capital Expenditures -4.3M -7.72M -12.1M -1.61M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -88.47M -43.6M 36.74M -71.2M
Net Income -88.29M -43.6M 36.74M -71.2M
Selling General Administrative 33.81M 36.34M 34.99M 37.25M
Gross Profit -57.29M -15.34M 62.38M -36.37M
Ebit -91.09M -51.68M 27.38M -73.62M
Operating Income -91.09M -51.68M 27.38M -73.62M
Interest Expense -390k -390k -390k -390k
Income Tax Expense -180k
Total Revenue 7.62M 104.39M 171.13M 37.41M
Cost Of Revenue 64.91M 119.73M 108.75M 73.79M
Total Other Income ExpenseNet 2.63M 8.08M 9.36M 2.42M
Net Income From Continuing Ops -88.29M -43.6M 36.74M -71.2M
Net Income Applicable To Common Shares -88.29M -43.6M 36.74M -71.2M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 130.58M 255.25M 107.26M 98.8M
Total Stockholder Equity 46.45M 99.51M 154.32M 95.06M
Other Current Liabilities 20.97M 47.23M 7.73M 33.89M
Total Assets 177.03M 354.76M 261.58M 193.85M
Common Stock 32k 37k 37k 38k
Other Current Assets 5.86M 3.95M 7.07M 2.05M
Retained Earnings -269.05M -312.65M -275.91M -347.1M
Treasury Stock -133k -104k -134k -138k
Cash 46.86M 86.04M 104.44M 117.43M
Total Current Liabilities 31.67M 76.01M 26.77M 50.98M
Other Stockholder Equity -133k -104k -134k -138k
Property, Plant, and Equipment 12.77M 46.46M 61.5M 55.38M
Total Current Assets 162.48M 304.66M 197.77M 136.7M
Net Tangible Assets 46.45M 99.51M 154.32M 95.06M
Net Receivables 201k 18.97M 8.11M 748k
Accounts Payable 1.04M 4.07M 634k 574k


Insider Transactions

Here are the insider transactions of stock shares related to Voyager Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
PFREUNDSCHUH PETER PStock Award(Grant) at price 0.00 per share.D2022-09-30Chief Financial Officer125k
THIRD ROCK VENTURES III, L.P.Sale at price 6.09 - 6.22 per share.I2022-08-25Beneficial Owner of more than 10% of a Class of Security349.97k
THIRD ROCK VENTURES III, L.P.Sale at price 6.04 per share.I2022-08-16Beneficial Owner of more than 10% of a Class of Security128.46k
THIRD ROCK VENTURES III, L.P.Sale at price 6.04 - 6.12 per share.I2022-08-15Beneficial Owner of more than 10% of a Class of Security483.81k
PIERCE GLENN FSale at price 6.70 per share.D2022-07-14Director9.51k
HIGGINS MICHAEL JSale at price 6.70 per share.D2022-07-14Director13.89k
ECOR1 CAPITAL, L.L.C.Purchase at price 5.28 - 5.66 per share.I2022-06-23Beneficial Owner of more than 10% of a Class of Security477.4k
HESSLEIN ROBERT WSale at price 8.25 per share.D2022-04-04General Counsel2.79k
SWARTZ ROBINSale at price 8.25 per share.D2022-04-04Chief Operating Officer1.53k
SANDROCK ALFRED W JRStock Award(Grant) at price 0.00 per share.D2022-03-22Chief Executive Officer100k
HESSLEIN ROBERT WSale at price 8.29 - 8.68 per share.D2022-03-21General Counsel4.96k
BUREK JULIESale at price 8.29 - 8.68 per share.D2022-03-21Officer2.65k
SWARTZ ROBINSale at price 8.29 - 8.68 per share.D2022-03-21Chief Operating Officer4.41k
HESSLEIN ROBERT WSale at price 3.55 per share.D2022-02-17General Counsel4.1k
BUREK JULIESale at price 3.55 per share.D2022-02-17Officer789
HESSLEIN ROBERT WSale at price 3.36 per share.D2022-02-11General Counsel3.25k
BUREK JULIESale at price 3.36 per share.D2022-02-11Officer361
PIERCE GLENN FStock Award(Grant) at price 0.00 per share.D2022-01-13Officer and Director26.3k
HIGGINS MICHAEL JStock Award(Grant) at price 0.00 per share.D2022-01-13Chief Executive Officer45.2k
HESSLEIN ROBERT WStock Award(Grant) at price 0.00 per share.D2022-01-13General Counsel20k
BUREK JULIEStock Award(Grant) at price 0.00 per share.D2022-01-13Officer10k
BUREK JULIESale at price 2.83 - 3.06 per share.D2022-01-12Officer3.33k
BUREK JULIEStock Award(Grant) at price 2.30 per share.D2021-12-31Officer3.06k
BUREK JULIEStock Award(Grant) at price 0.00 per share.D2021-11-26Officer13.5k
KHWAJA OMAR M.D. PH.D.Sale at price 4.03 per share.D2021-05-21Officer3.52k
HESSLEIN ROBERT WSale at price 4.95 per share.D2021-04-05General Counsel3.29k
HESSLEIN ROBERT WStock Award(Grant) at price 0.00 per share.D2021-03-19General Counsel30k
DORVAL ALLISONStock Award(Grant) at price 0.00 per share.D2021-03-19Chief Financial Officer30k
TURENNE G ANDREStock Award(Grant) at price 0.00 per share.D2021-03-19Chief Executive Officer80k
KHWAJA OMAR M.D. PH.D.Stock Award(Grant) at price 0.00 per share.D2021-03-19Officer35k
HESSLEIN ROBERT WStock Award(Grant) at price 0.00 per share.D2021-02-16General Counsel34k
DORVAL ALLISONStock Award(Grant) at price 0.00 per share.D2021-02-16Chief Financial Officer34k
TURENNE G ANDREStock Award(Grant) at price 0.00 per share.D2021-02-16Chief Executive Officer94k
KHWAJA OMAR M.D. PH.D.Stock Award(Grant) at price 0.00 per share.D2021-02-16Officer36k
HESSLEIN ROBERT WSale at price 7.55 per share.D2021-02-11General Counsel3.19k
DORVAL ALLISONSale at price 7.55 per share.D2021-02-11Chief Financial Officer3.19k
TURENNE G ANDRESale at price 7.55 per share.D2021-02-11Chief Executive Officer7.98k
KHWAJA OMAR M.D. PH.D.Sale at price 7.55 per share.D2021-02-11Officer3.48k
DORVAL ALLISONSale at price 8.62 per share.D2021-01-12Chief Financial Officer2.94k
TURENNE G ANDRESale at price 8.62 per share.D2021-01-12Chief Executive Officer10.44k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Voyager Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Voyager Therapeutics Inc

Here is the result of two systematic investment strategies applied to Voyager Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Voyager Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Voyager Therapeutics Inc:

Voyager Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -67.1% on the backtest period.

Performance at glance

Performance

-67.1 %

Latent gain

-1517.17 $

Invested capital

2260.99 $

Annualized return

-16.21 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Voyager Therapeutics Inc

This is the result of two momentum investment strategies applied to Voyager Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Voyager Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Voyager Therapeutics Inc:

Voyager Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -65.37% of return on Voyager Therapeutics Inc. That represents -3263.66$ of latent gain with 4992.39$ of employed capital.
  • The second momentum investment strategy would give -70.12% of return on Voyager Therapeutics Inc. That represents -2118.46$ of latent gain with 3021.04$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-65.37 %

Latent gain

-3263.66 $

Invested capital

4992.39 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-70.12 %

Latent gain

-2118.46 $

Invested capital

3021.04 $

Annualized return

-19.16 %

Momentum equity curve on Voyager Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Voyager Therapeutics Inc:

Voyager Therapeutics Inc momentum equity

Note: the dividends potentially given by Voyager Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Voyager Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Voyager Therapeutics Inc since the beginning:

Voyager Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Voyager Therapeutics Inc

Buy the dip entry openings on Voyager Therapeutics Inc

Voyager Therapeutics Inc

The performance achieved by the robo-advisor on Voyager Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Voyager Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Voyager Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Voyager Therapeutics Inc

The following chart shows the result of the investment strategy applied to Voyager Therapeutics Inc:

Voyager Therapeutics Inc

Note: the dividends potentially given by Voyager Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Voyager Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Voyager Therapeutics Inc:

Voyager Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Voyager Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Voyager Therapeutics Inc.

Equity curve comparison on Voyager Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Voyager Therapeutics Inc investment strategy comparison

Employed capital comparison on Voyager Therapeutics Inc

Voyager Therapeutics Inc investment comparison

Performance comparison on Voyager Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -67.1% -1517.17$ 2260.99$ -16.21%
Momentum 1 quarter -65.37% -3263.66$ 4992.39$ -16.76%
Momentum 2 quarters -70.12% -2118.46$ 3021.04$ -19.16%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-16.21 %

Momentum 1Q

-19.16 %

Momentum 2Q

-19.16 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Voyager Therapeutics Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • Palomar Holdings Inc
  • GREENTOWN CHINA

  • Note: The algorithm computes the probability of correlation between Voyager Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Voyager Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Voyager Therapeutics Inc
    Country United States
    City Cambridge
    Address 75 Sidney Street
    Phone 857 259 5340
    Website www.voyagertherapeutics.com
    FullTime employees 101
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker VYGR
    Market www.nasdaq.com

    Voyager Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown